Renaissance Technologies LLC Has $17.98 Million Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Renaissance Technologies LLC raised its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 56.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 595,800 shares of the company’s stock after purchasing an additional 215,700 shares during the quarter. Renaissance Technologies LLC owned 1.05% of Harmony Biosciences worth $17,975,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Harmony Biosciences by 9.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 319,167 shares of the company’s stock worth $10,309,000 after buying an additional 28,256 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Harmony Biosciences by 31.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 27,509 shares of the company’s stock valued at $889,000 after purchasing an additional 6,571 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in shares of Harmony Biosciences by 47.5% in the fourth quarter. Quadrant Capital Group LLC now owns 1,022 shares of the company’s stock valued at $33,000 after purchasing an additional 329 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Harmony Biosciences in the fourth quarter worth $432,000. Finally, Franklin Resources Inc. acquired a new position in Harmony Biosciences during the fourth quarter worth $876,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analyst Upgrades and Downgrades

HRMY has been the topic of several recent research reports. UBS Group began coverage on shares of Harmony Biosciences in a research note on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research report on Thursday, September 12th. Finally, Citigroup started coverage on Harmony Biosciences in a research report on Friday, June 21st. They set a “buy” rating and a $48.00 price target for the company. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $41.33.

Harmony Biosciences Trading Up 0.8 %

Harmony Biosciences stock opened at $39.29 on Friday. The stock has a 50-day simple moving average of $35.22 and a 200 day simple moving average of $32.26. The stock has a market capitalization of $2.23 billion, a P/E ratio of 17.01, a PEG ratio of 0.75 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 3.09 and a current ratio of 3.13. Harmony Biosciences Holdings, Inc. has a 52 week low of $18.61 and a 52 week high of $39.73.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, August 6th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.24. The company had revenue of $172.80 million during the quarter, compared to the consensus estimate of $172.53 million. Harmony Biosciences had a return on equity of 22.97% and a net margin of 17.53%. The firm’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.56 EPS. Analysts expect that Harmony Biosciences Holdings, Inc. will post 2.19 earnings per share for the current year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.